3413 studies found for:    "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
2 Active, not recruiting Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immune System Diseases
Interventions: Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Procedure: Allogeneic hematopoietic stem cell transplantation
3 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
4 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
5 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
6 Completed A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: Filgrastim;   Drug: Stavudine;   Drug: Cyclophosphamide
7 Completed A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoplasms;   Neoplasms by Site;   Breast Diseases;   Skin Diseases
Intervention: Drug: ET743
8 Recruiting Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
Conditions: Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Peritoneal Cancer
Interventions: Biological: DPX-Survivac;   Drug: Cyclophosphamide;   Drug: Epacadostat (INCB024360)
9 Not yet recruiting Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Leukemia
Interventions: Drug: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);   Drug: Cytarabine(Actavis Italy S.p.A);   Drug: Fludarabine (Bayer);   Drug: granulocyte colony-stimulating factor (KirinKunpeng);   Drug: rabbit ATG(Sanofi/Genzyme)
10 Recruiting Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
Condition: Intracranial Non-germinomatous Germ Cell Tumor
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Bleomycin;   Drug: Thiotepa;   Drug: Melphalan;   Radiation: Reduced dose radiotherapy
11 Recruiting Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
Condition: Unresectable Localized Soft Tissue Sarcoma
Interventions: Drug: Cisplatin;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Radiation: Radiotherapy;   Drug: Thiotepa;   Drug: Melphalan
12 Recruiting Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
Condition: Intracranial Germinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Bleomycin;   Radiation: Reduced dose of radiotherapy
13 Not yet recruiting Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
14 Not yet recruiting Temozolomide Chronotherapy for High Grade Glioma
Conditions: Glioma;   Glioblastoma Multiforme
Interventions: Drug: Temozolomide;   Other: Functional Assessment of Cancer Therapy - Brain;   Other: Wrist actimetry device
15 Not yet recruiting A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
16 Not yet recruiting Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous Hematopoietic Cell Transplantation (HCT)
17 Recruiting Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
Condition: Glioblastoma Multiforme
Intervention: Drug: Metformin
18 Recruiting HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
Condition: Sickle Cell Disease
Intervention: Drug: Fludarabine monophosphate
19 Not yet recruiting Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Conditions: Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
Interventions: Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
20 Not yet recruiting Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1
Conditions: HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
Interventions: Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years